Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 5,232 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Infection Clear all

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 34
States / cities: Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 27 more

Conditions: HIV Infections
Interventions: Zidovudine, Acyclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 3
States / cities: Los Angeles, California • San Diego, California • Seattle, Washington

Conditions: COVID-19 Disease
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Bacterial Infections.
Interventions: Dalbavancin; Drug
Lead sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc; Industry
Eligibility: 3 Months to 11 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 10
States / cities: Little Rock, Arkansas • San Diego, California • Hartford, Connecticut + 7 more

Conditions: Vesicoureteral Reflux
Interventions: Parental information, Play therapy; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 2 Years to 10 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cardiac Implantable Electronic Device Infection, Cardiovascular Infections
Interventions: Force gauge; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Plaque Psoriasis.
Interventions: Gadolinium, Efficacy of Enbrel subcutaneously at Week 12, Efficacy of Enbrel subcutaneously at Week 24, Efficacy of Enbrel subcutaneously at Week 36, Efficacy of Enbrel subdermally at Week 12, Efficacy of Enbrel subdermally at Week 24, Efficacy of Enbrel subdermally at Week 36, PASI 75 n(%) subcutaneously at Week 12, PASI 75 n(%) subcutaneously at Week 24, PASI 75 n(%) subcutaneously at Week 36, PASI 75 n(%) subdermally at Week 12, PASI 75 n(%) subdermally at Week 24, PASI 75 n(%) subdermally at Week 36, Adverse Reactions of Enbrel subcutaneously, Adverse Reactions of Enbrel subdermally at Week 36; Drug
Lead sponsor: ASIS Corporation; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Westminster, California

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimetrexate glucuronate, Pentamidine isethionate, Sulfamethoxazole-Trimethoprim, Leucovorin calcium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 23
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 15 more

Conditions: Skin Infections
Interventions: PZ-601, Standard of Care; Drug
Lead sponsor: Protez Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 15
States / cities: Chula Vista, California • Fountain Valley, California • Long Beach, California + 12 more

Conditions: Self Efficacy, HIV Prevention, STI Prevention
Interventions: Treat Act Know Engage (T.A.K.E.) Steps, Standard or Care; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 13 Years to 19 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Philadelphia, Pennsylvania

Conditions: COVID-19 SARS-CoV-2 Infection
Interventions: ibuzatrelvir, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 2,330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 90
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Bakersfield, California + 66 more

Conditions: Rabies in Animals, Worms; Intestine
Interventions: integrated delivery of deworming and vaccination, Mass deworming only, Mass vaccination of dogs; Other
Lead sponsor: Washington State University; Other
Eligibility: Not listed
Enrollment: 28,143 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Wound, Bacterial Infections, Diabetes Mellitus, Infected Ulcer of Skin
Interventions: Finger prick test for HbA1c measurement, Punch Biopsy, Vac Sponge Collection, Ankle Brachial Index; Diagnostic Test · Procedure · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: Indianapolis, Indiana • Columbus, Ohio

Conditions: Urinary Tract Infection
Interventions: E. coli 83972 coated urinary catheter; Device
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 50 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Infections Resistant to Multiple Drugs, Bacterial Infections
Interventions: Standard of Care; Other
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 6,496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: COVID-19
Interventions: LY3819253, Placebo, Remdesivir; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 42
States / cities: Tucson, Arizona • Fresno, California • Los Angeles, California + 32 more

Conditions: HIV Infections
Interventions: Truvada, Genvoya; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hepatitis C
Interventions: Patient-Centered Electronic App; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bacteremia, Fungemia, Bloodstream Infection
Interventions: FilmArray testing, Antimicrobial Stewardship, Bacterial culture, Susceptibility testing; Device · Behavioral · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: Up to 99 Years
Enrollment: 743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HIV-1-infection
Interventions: Oral Lenacapavir, Oral Lenacapavir Placebo, Subcutaneous Lenacapavir, Failing ARV Regimen, Optimized Background Regimen (OBR); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 12 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 35
States / cities: Los Angeles, California • Palm Springs, California • Sacramento, California + 28 more

Conditions: Cystic Fibrosis, Lung Disease, Pseudomonas Infections
Interventions: CF newborn screening; Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 1 Month to 21 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Burnout, Mental Health
Interventions: Mindful Hand Hygiene; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Houston, Texas

Conditions: Pancreatitis, Acute Necrotizing
Interventions: meropenem; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 9
States / cities: San Francisco, California • Tampa, Florida • Chicago, Illinois + 6 more

Conditions: HIV Infections
Interventions: Nonoxynol-9; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 4,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2001
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Search by objective public record fields.

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection

A Study of Zidovudine Plus Acyclovir in HIV-Infected Patients

VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease

A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.

Parent Education and Medical Play: A Comparison of Psychological Preparation Strategies for Voiding Cystourethrogram

Improving Safety of Lead Extraction Procedures by Traction Force Sensing

ASIS for Enbrel in Plaque Psoriasis

Comparison of Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

Safety, Potential Efficacy, and Pharmacokinetics of PZ-601 in the Treatment of Complicated Skin and Skin Structure Infection

TAKE Steps: Motivational Interviewing to Prevent STIs

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Integrating Community Interventions to Eliminate Neglected Tropical Diseases

Biofilm Modified Macrophage Phenotype and Function in Diabetic Wound Healing

Bacterial Interference for Prevention of Catheter-Associated UTI: Geriatric Pilot Study

Multi-Drug Resistant Organism Network

LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities

Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum

Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance

Benefits and Risks of Newborn Screening for Cystic Fibrosis

Mindful Hand Hygiene for Healthcare Workers

A Study to Determine if Antibiotics Prevent Infection in the Pancreas of Patients Where Part of the Pancreas Has Died

A Study of Nonoxynol-9 (N-9) and HIV Infection